HANALL BIOPHARMA CO.,LTD Logo

HANALL BIOPHARMA CO.,LTD

Develops innovative medicines for chronic diseases through antibody and small molecule research.

009420 | KO

Overview

Corporate Details

ISIN(s):
KR7009420001
LEI:
Country:
South Korea
Address:
대전광역시 대덕구 상서당1길 43, 대전광역시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

HanAll Biopharma Co., Ltd. is a global biopharmaceutical company dedicated to the research and development of innovative, first-in-class medicines for patients with incurable and chronic diseases. The company's core mission is centered on pioneering cutting-edge, disease-modifying therapeutics. Its R&D specializes in antibody research, biotherapeutics, and new small molecule discovery. For over 50 years, HanAll has operated a commercial portfolio of pharmaceutical products targeting a range of therapeutic areas, including endocrine, circulatory, and urologic diseases, while advancing its global pipeline to address significant unmet medical needs.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.5 MB
2025-07-30 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 29.1 KB
2025-07-30 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.7 KB
2025-07-30 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.5 KB
2025-06-02 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 28.7 KB
2025-06-02 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.3 KB
2025-06-02 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 27.0 KB
2025-06-02 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.4 KB
2025-05-30 00:00
Governance Information
기업지배구조보고서공시
Korean 758.3 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.5 MB
2025-04-30 00:00
Earnings Release
연결재무제표기준영업(잠정)실적(공정공시)
Korean 15.7 KB
2025-04-30 00:00
Transaction in Own Shares
주요사항보고서(자기주식처분결정)
Korean 29.2 KB
2025-04-30 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.1 KB
2025-04-30 00:00
Major Shareholding Notification
최대주주등소유주식변동신고서
Korean 27.0 KB
2025-04-30 00:00
Transaction in Own Shares
자기주식처분결과보고서
Korean 16.8 KB

Automate Your Workflow. Get a real-time feed of all HANALL BIOPHARMA CO.,LTD filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for HANALL BIOPHARMA CO.,LTD

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for HANALL BIOPHARMA CO.,LTD via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

ArcticZymes Technologies Logo
Develops novel enzymes from Arctic organisms for diagnostics, therapeutics, and biopharma.
Norway
AZT
Arcturus Therapeutics Holdings Inc. Logo
Develops mRNA therapeutics and vaccines for rare respiratory, liver, and infectious diseases.
United States of America
ARCT
Arcus Biosciences, Inc. Logo
A clinical-stage biopharma developing small molecule and antibody combination therapies for cancer.
United States of America
RCUS
Arcutis Biotherapeutics, Inc. Logo
Develops and commercializes non-steroidal therapies for immune-mediated skin diseases.
United States of America
ARQT
ARDELYX, INC. Logo
Biopharma developing first-in-class drugs for cardiorenal and GI diseases like IBS-C and CKD.
United States of America
ARDX
ARECOR THERAPEUTICS PLC Logo
Biopharma firm enhancing drugs via reformulation for diabetes and pharmaceutical partners.
United Kingdom
AREC
argenx SE Logo
Develops first-in-class antibody therapies for severe autoimmune diseases.
Netherlands
1AE
Armata Pharmaceuticals, Inc. Logo
Developing bacteriophage therapeutics for antibiotic-resistant infections.
United States of America
ARMP
AroCell AB Logo
Develops and markets diagnostic tests for monitoring cancer and bacterial diseases.
Sweden
AROC
ArriVent BioPharma, Inc. Logo
A clinical-stage biopharma developing in-licensed oncology drugs for difficult-to-treat diseases.
United States of America
AVBP

Talk to a Data Expert

Have a question? We'll get back to you promptly.